

Translational Research on Neuropharmacology and Movement Disorders
A Phase IIA clinical trial for treating LID using a novel small molecule performed in collaboration with our clinical team has yielded positive results. Click below to download the full press release.
Funding of 19.96M SEK to conduct an RCT of Montelukast for treating Parkinson’s disease has been awarded to the group. Link for more information can be found here.
Link to the news article can be found here
Our paper peeling back the pharmacology behind the new antipsychotic SEP-856 (Ulotaront) can be accessed here
Link to Per’s page can be found here